X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-present-healthcare-resource-utilization-data-in-radicava-ors-edaravone-treated-als-patients-at-amcp-2024-302115041.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-receives-us-food-and-drug-administration-orphan-drug-exclusivity-for-radicava-ors-edaravone-302109933.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-post-hoc-analysis-examining-effect-of-early-intervention-with-radicava-edaravone-on-survival-and-disease-progression-milestones-in-people-with-als-301903644.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-celebrates-one-year-anniversary-of-radicava-ors-edaravone-launch-in-the-us-301851331.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-edaravone-oral-suspension-15938.pdf
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-present-latest-findings-across-als-and-parkinsons-disease-at-2023-american-academy-of-neurology-annual-meeting-301802571.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-enrollment-completion-for-global-phase-3b-study-of-radicava-ors-edaravone-in-als-301779833.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-more-than-10-000-people-with-als-treated-with-radicava-ors-edaravone-andor-radicava-edaravone-301773547.html
https://www.prnewswire.com/news-releases/radicava-ors-edaravone-added-to-us-department-of-veterans-affairs-national-formulary-301768724.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-nearly-4-000-als-patients-in-the-us-have-been-treated-with-radicava-ors-edaravone-301731026.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-presents-data-on-radicava-ors-edaravone-at-2022-aanem-annual-meeting-301629599.html
https://endpts.com/icer-panel-says-two-als-drug-candidates-have-low-long-term-value/
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-real-world-data-analysis-of-survival-with-radicava-edaravone-301605696.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-long-term-findings-from-post-marketing-safety-study-of-radicava-edaravone-301577865.html
https://www.prnewswire.com/news-releases/radicava-ors-edaravone-now-available-in-the-us-for-the-treatment-of-als-301568612.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-presents-48-week-results-from-global-phase-3-safety-clinical-study-of-radicava-ors-edaravone-an-oral-treatment-for-als-301558944.html
https://www.prnewswire.com/news-releases/fda-approves-radicava-ors-edaravone-oral-suspension-for-the-treatment-of-amyotrophic-lateral-sclerosis-als-by-mitsubishi-tanabe-301556040.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-presents-real-world-data-on-radicava-edaravone-at-2022-american-academy-of-neurology-annual-meeting-301516649.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-fda-acceptance-of-new-drug-application-nda-for-oral-edaravone-formulation-for-the-treatment-of-als-301459460.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-results-from-the-global-phase-3-safety-study-of-investigational-oral-edaravone-in-the-treatment-of-als-301441286.html
https://www.prnewswire.com/news-releases/post-hoc-analysis-of-phase-3-study-examines-effect-of-early-intervention-with-edaravone-on-survival-and-disease-progression-milestone-events-in-als-patients-301250276.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-presents-real-world-experience-outcomes-during-iv-edaravone-treatment-at-virtual-31st-international-symposium-on-alsmnd-301191155.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-the-global-phase-3-study-of-oral-edaravone-for-als-has-completed-enrollment-301168802.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-presentations-at-northeast-amyotrophic-lateral-sclerosis-19th-annual-meeting-301140408.html
https://www.biospace.com/article/releases/mitsubishi-tanabe-pharma-canada-announces-treatment-for-amyotrophic-lateral-sclerosis-als-now-eligible-for-coverage-through-veterans-affairs-canada-and-indigenous-services-canada/
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-enrollment-has-resumed-for-the-global-phase-3-study-of-oral-edaravone-for-als-301117035.html
https://www.biospace.com/article/releases/mitsubishi-tanabe-pharma-canada-announces-that-treatment-for-amyotrophic-lateral-sclerosis-als-has-been-added-to-british-columbia-pharmacare-formulary/
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-honors-third-anniversary-of-radicava-edaravone-in-the-us--companys-support-of-als-community-301107586.html
https://www.biospace.com/article/releases/mitsubishi-tanabe-pharma-canada-announces-that-manitoba-has-added-the-company-s-treatment-for-amyotrophic-lateral-sclerosis-als-to-its-provincial-drug-formulary/
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-launch-of-the-journeymate-program-offering-live-nurse-educational-phone-support-for-als-patients-and-caregivers-301062602.html
https://markets.businessinsider.com/news/stocks/mitsubishi-tanabe-pharma-canada-announces-that-company-s-treatment-for-amyotrophic-lateral-sclerosis-als-has-been-added-to-the-provincial-drug-plan-in-quebec-1029145170
https://www.newswire.ca/news-releases/mitsubishi-tanabe-pharma-canada-concludes-letter-of-intent-with-pan-canadian-pharmaceutical-alliance-for-radicava-r-edaravone--829656128.html
https://www.prnewswire.com/news-releases/new-post-hoc-analysis-of-phase-3-study-examines-edaravone-in-als-patients-with-bulbar-and-limb-onset-301029107.html
http://www.pharmatimes.com/news/first_patient_enrolled_in_oxford_biodynamics_als_biomarker_study_1314536
https://www.biospectrumasia.com/news/25/14506/mitsubishi-tanabe-daiichi-sankyo-tie-alliance-for-als-treatment-agent.html
https://www.prnewswire.com/news-releases/more-than-4-000-us-patients-with-als-treated-with-radicava-edaravone-in-two-years-since-availability-mitsubishi-tanabe-pharma-america-reports-300898831.html
https://www.fiercepharma.com/pharma/mitsubishi-tanabe-s-radicava-stalls-eu-after-approval-body-asks-for-further-als-study
https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-samsung-biologics-crisis-gardasil-supply-china-s-vaccine-regulation
https://www.fiercepharma.com/marketing/mitsubishi-tanabe-spotlights-overlooked-teen-role-caring-for-als-loved-ones-new-effort
https://www.fiercebiotech.com/orion-take-repurposed-heart-failure-drug-into-phase-3-for-als
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-present-data-on-radicava-edaravone-at-the-european-network-for-the-cure-of-als-encals-annual-meeting-300670274.html
https://www.newswire.ca/news-releases/health-canada-accepts-mitsubishi-tanabe-pharma-corporations-nds-filing-for-edaravone-to-treat-als-grants-priority-review-679175713.html
https://www.fiercebiotech.com/biotech/after-disappointing-2016-new-drug-approvals-roared-back-to-life-2017
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-present-data-on-radicava-edaravone-at-28th-international-symposium-on-alsmnd-in-boston-300566746.html
http://www.fiercepharma.com/marketing/payers-line-up-to-back-mitsubishi-tanabe-s-pricey-new-als-therapy
https://thewest.com.au/news/australia/pfizer-blood-thinning-warning-after-pills-mix-up-ng-b88566115z
https://www.upi.com/Health_News/2017/08/11/Two-ALS-patients-in-Buffalo-first-in-US-to-receive-new-drug/4781502472653/?utm_source=sec&utm_campaign=sl&utm_medium=2
https://scicasts.com/channels/bio-it/1858-drug-development/12625-ai-based-personalized-drug-discovery-platform-launched/
http://www.pmlive.com/pharma_news/fda_clears_new_als_drug_radicava_ahead_of_schedule_1192437
Market Place
Share 
